What is Morpheus8?

Morpheus8 is a fractional radiofrequency microneedling system manufactured by InMode Ltd. (Yokneam, Israel). It delivers bipolar RF through coated, insulated microneedles to depths up to 4.0 mm under its original FDA 510(k) clearance, K192695 (December 27, 2019). A second clearance, K240017 (June 13, 2024), added the Morpheus8 90 Applicator and broadened the indications language to include coagulation or contraction of soft tissue in dermatological procedures. The system runs on InMode, EmPowerRF, and Envision platforms and uses a family of single-use tip heads in 12, 24, 40, T, and 90 pin configurations.

How Morpheus8 works: bipolar fractional RF through coated microneedles

Morpheus8 is part of the broader category of RF microneedling, a modality that delivers radiofrequency energy into the dermis through a grid of fine needles rather than across the skin surface. The “fractional” part means the energy is deposited in a pattern of treated columns separated by untreated tissue, which is the mechanism most current bipolar microneedling systems share. What sets Morpheus8 apart from several other devices in the category is its needle design and depth range.

The needles are bipolar and coated, with insulation along most of the needle shaft and an exposed tip. The intent of the coating is to concentrate the RF energy at the needle tip rather than along the full length of the shaft. This is one of the structural differences between Morpheus8 and other RF microneedling systems that use non-insulated needles, such as the Sylfirm X and Scarlet SRF platforms from VIOL.

Under K192695, the cleared specifications for the InMode System with the Morpheus8 (Fractora) Applicators include a maximum RF output of 65 W, an operating frequency of 1 MHz with a tolerance of plus or minus 2 percent, and a maximum treatment depth of 4.0 mm, with the T tip head fixed at 0.5 mm. The energy delivered per pin is configurable. At energy levels above 62 mJ per pin, the cleared labeling restricts use to Skin Types I to IV.

Clinics that look beyond a single brand for category context can review the broader RF microneedling tips and cartridges catalog to see how Morpheus8 sits alongside other devices in the same modality.

The Morpheus8 tip family: configurations and applicators

Morpheus8 is not a single tip on a single applicator. Across the FDA 510(k) clearances and the AccessGUDID listings under InMode Ltd., the catalog includes five tip configurations cited directly in FDA primary documents and several additional applicators and tips listed in GUDID under separate submissions. The table below separates the two groups so the regulatory provenance of each tip is visible.

Compatibility is based on industry-standard usage and clinical experience.

Two practical notes for procurement. First, tip generations track to applicator generations through InMode catalog numbering. Catalog prefixes in the AG6074xx and AG6091xx series belong to the first applicator generation, including the original Morpheus8 Applicator and the Morpheus8 Body (Blue). Prefixes in the AG6130xx and AG6131xx series belong to the second generation, which includes the Burst Applicator, Burst Deep Applicator, and 90 Applicator. The consumables article in this series covers the per-tip mapping in more detail.

Second, GUDID submissions for the Morpheus8 Burst Applicator reference K221571, K231790, K251254, and K251632. Clearance language for those submissions was not reviewed in primary source for this article, so the table treats Burst tips as listed in GUDID rather than directly cited from a Summary of Safety and Effectiveness.

FDA clearance status: K192695 and K240017

Morpheus8 holds two FDA 510(k) clearances that together cover the applicator and tip families used by clinics today. Both are Class II devices regulated under 21 CFR 878.4400, the section that covers electrosurgical cutting and coagulation devices and accessories. Both list Product Code GEI. Both list InMode Ltd. (Yokneam, Israel) as the applicant.

The original clearance is K192695 in the FDA 510(k) database, cleared on December 27, 2019. It covers the InMode System with the Morpheus8 (Fractora) Applicators, including the 12, 24, 40, and T pin tip heads, and was cleared as substantially equivalent to predicate K180189 (InMode System with Fractora3D and 3D-90 Applicators, cleared June 1, 2018). The published indications for use are:

The InMode System with the Morpheus8 (Fractora) Applicators is intended for use in Dermatologic and General Surgical procedures for Electrocoagulation and Hemostasis. At higher energy levels greater than 62 mJ/pin, use of the Morpheus8 (Fractora) Applicator is limited to Skin Types I-IV.

The second clearance is K240017, cleared on June 13, 2024. It adds the Morpheus8 90 Applicator and broadens the indications language to include contraction of soft tissue as a qualifying purpose in dermatological procedures:

The InMode System with the Morpheus8 90 Applicator is intended for use in dermatological procedures where coagulation/contraction of soft tissue or hemostasis is needed. At higher energy levels greater than 62 mJ/pin, the use of the Morpheus8 90 Applicator is limited to Skin Types I-IV.

Two clarifications matter for clinic procurement. First, both clearances use the FDA term "cleared," not "approved." A 510(k) clearance establishes substantial equivalence to a legally marketed predicate device; it is not the premarket approval pathway used for Class III devices. In practical buying terms, that distinction belongs to regulatory category rather than to product quality. Aesthetic RF and energy-based devices on the US market almost universally enter through the 510(k) pathway rather than premarket approval. Second, marketing literature describes a body applicator with treatment depths up to 8 mm. K192695 lists a maximum treatment depth of 4.0 mm. The 8 mm figure should be verified per specific applicator generation against the relevant FDA 510(k) summary or current device labeling before being relied on for clinical decisions.

What clinics use Morpheus8 for

Clinics use Morpheus8 for a range of dermatologic indications consistent with the cleared intended-use language. Common clinical contexts include skin laxity, fine lines, acne scarring, and other scar revision work, with deeper applicators sometimes selected for body contouring contexts where the K240017 language around contraction of soft tissue is relevant. The dedicated body applicators and depth article cover this in more detail. The specific decision on treatment area, depth setting, energy per pin, and number of passes belongs with the treating practitioner; it is not part of the FDA-published clearance language.

For B2B planning purposes, the practical distinctions between Morpheus8 applicators matter more than the marketing categories. The 12 and 24 pin tips concentrate energy in smaller arrays often selected for facial work and finer treatment patterns. The 40 pin and the Body tips spread energy over a larger area and are commonly chosen for body work. The 90 Applicator under K240017 extends the range of cleared configurations into a larger pin array for soft tissue contexts. Suitability for any given case remains a clinical determination, not a device-driven default.

One protocol detail returns to the cleared labeling. The energy delivered per pin and the depth setting are independent dials in the device's interface, and the 62 mJ per pin ceiling for Skin Types V and VI applies to the energy variable, not to the depth setting. A clinic treating a patient with Skin Type V at a lower depth still needs to stay under the energy threshold to remain inside the cleared labeling envelope. The treating practitioner decides which combination of depth, energy, pass count, and tip configuration is appropriate for the case; Morpheus8 documentation supports that decision rather than substituting for it.

Morpheus8 platforms: InMode, EmPowerRF, and Envision

Morpheus8 is delivered through applicators connected to a platform, not as a standalone box. AccessGUDID lists three InMode platforms that carry Morpheus8 applicators among their components, each with its own FDA product codes:

Three GUDID-level details are worth noting for clinics evaluating secondhand or refurbished platforms. Tips are lot-tracked. Applicators and platforms are serial-tracked. Sterilization prior to use is listed as "No" for the applicators and platforms, and tips are listed as packaged sterile under gamma sterilization where the FDA Summary documents this. The device and equipment article in this series goes into platform selection in more depth.

Morpheus8 and related RF microneedling brands

Morpheus8 sits in a broader FDA classification family. All of the leading bipolar RF microneedling devices on the US market share the same Class II classification under 21 CFR 878.4400 and Product Code GEI. That shared classification does not mean the devices share a regulatory family. Morpheus8 traces its predicate chain through InMode submissions (K180189 Fractora3D leading to K192695 leading to K240017). The Sylfirm X and Scarlet SRF platforms from VIOL share a different predicate family (Celfirm K172023 and Scarlet K180872, both leading to Sylfirm X K200185).

The practical implication for procurement is that "same FDA classification" and "same technology family" are not the same statement. Pinova carries tips and consumables across multiple RF microneedling brands in the portfolio, and the cleared specifications of each system are best read against the corresponding 510(k) summary rather than read by analogy across brands. The Morpheus8 comparison hub across treatment modalities goes through the broader landscape (HIFU, mechanical microneedling, monopolar RF, ablative laser) in more depth than this brand overview does.

Professionally sourced Morpheus8 tips: how Pinova carries them

Pinova carries professionally sourced Morpheus8 tips for clinics that maintain InMode Morpheus8 platforms in their treatment portfolio. Inventory covers the standard tip configurations across both applicator generations, with catalog detail visible on the collection page. Verification against the specific applicator and platform in use is the responsibility of the buying clinic. Per-session cost economics for Morpheus8 sit in the cost framework for clinics; SKU-level tip catalog detail sits in InMode Morpheus8 Tips.

Frequently asked questions

What is Morpheus8?

Morpheus8 is a fractional bipolar RF microneedling system manufactured by InMode Ltd. It uses coated, insulated microneedles to deliver radiofrequency energy into the dermis. It is cleared by the FDA under two 510(k) submissions, K192695 (2019) and K240017 (2024), and is delivered through applicators connected to the InMode, EmPowerRF, or Envision platform.

Is Morpheus8 FDA cleared?

Yes. Morpheus8 is cleared by the FDA under 510(k) submissions K192695 (December 27, 2019) and K240017 (June 13, 2024). Both are Class II devices regulated under 21 CFR 878.4400 with Product Code GEI. The FDA uses the term "cleared," which reflects substantial equivalence to a predicate device under the 510(k) pathway; this is not the premarket approval process used for Class III devices.

What does Morpheus8 do?

Morpheus8 delivers bipolar radiofrequency energy into the dermis through a fractional array of coated microneedles. Under the K192695 indications, it supports electrocoagulation and hemostasis in dermatologic and general surgical procedures. Under the K240017 indications for the 90 Applicator, the cleared language additionally covers coagulation or contraction of soft tissue in dermatological procedures.

What is fractional RF microneedling?

Fractional RF microneedling is a category of bipolar radiofrequency devices that deliver energy into the dermis through a grid of fine needles rather than across the skin surface. The "fractional" pattern leaves untreated tissue between treated columns. Different devices in the category use coated or non-insulated needles, different pin counts, and different depth ranges; Morpheus8 is one device in that broader category.